bullish
Concord Biotech (Pre-IPO): Niche Offering Amid Lean Competition to Drive Stable Growth
281 Views02 Aug 2023 18:16
SUMMARY
- Concord Biotech Ltd (658823Z IN) is amongst the few fermentation-based API manufacturing companies globally. The company commanded market share of 20%+ by volume in 2022 across identified fermentation‐based API products.
- Concord Biotech IPO opens for subscription on August 4. The IPO consists of offer for sale of 21M shares by Helix Investment Holdings at a price band of INR705–741/share.
- Large and growing addressable market, sizable market share, niche and limited competition offering, consistent growth and profitability, and reasonable valuation make the IPO worth of subscribing.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Concord Biotech Ltd (CONCORDB IN): Accelerated Growth Ahead; Recent Pullback Comforted Valuation11 Jun 2024
- Concord Biotech's US$650m Lock-Up Expiry - Some Could Be Tempted to Book Multi-Bagger Gains06 Feb 2024
- Concord Biotech Ltd (658823Z IN): Q2 EBITDA and PAT Triples on Operational Efficiencies01 Dec 2023
- Concord Biotech (Pre-IPO): Niche Offering Amid Lean Competition to Drive Stable Growth02 Aug 2023
- Concord Biotech IPO - RHP Updates - Continued Growing Although Concentration Risk Remains Elevated02 Aug 2023
- Concord Biotech Pre-IPO - Sales Have Been Growing but Watch Out for Its High Concentration Risk30 Jan 2023
- Concord Biotech Pre-IPO Tearsheet24 Aug 2022
x